A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept. With up to 8 years of followup, a significant degree of biologic switching was observed. Complete remission was achieved in more than half of patients. Numerous (24) serious adverse events were seen, including numerous infections, macrophage activation syndrome, ANCA+ glomerulonephritis and Crohn’s colitis.
Author: creativebananas
Related Content
-
November 26, 2019A disease you’ve never heard of is becoming increasingly common and carries a…
-
August 8, 2019A single-center cohort analysis shows that lung disease (LD) is increasingly seen in…
-
January 17, 2018Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile…
-
January 1, 1970
Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked…
-
November 9, 2021 -
April 5, 2018The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6…